Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 16/20 | 0.69 |
| ▸ | TTR | P02766 | 11/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395715 | 0.88 | RBP4 (0.69) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL27680981 | 0.82 | KDM4E (0.60) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL6395920 | 0.81 | NAPEPLD (0.52) | RBP4KDM4EHPGDHSD17B10 | |
| SCHEMBL13494044 | 0.81 | KDM4E (0.81) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL27681034 | 0.79 | RBP4 (0.56) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL1179851 | 0.79 | RBP4 (0.59) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL24851277 | 0.78 | GBA1 (0.58) | — | |
| SCHEMBL12552670 | 0.78 | RBP4 (0.55) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL30637298 | 0.78 | RBP4 (0.64) | RBP4TTRKDM4EUSP2HPGD | |
| SCHEMBL5216228 | 0.78 | RBP4 (0.57) | RBP4TTRKDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282824-A1 | Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems | LI XIAOBING | 2005-12-22 | — | — | US | disclosed |
| WO-2005113514-A2 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282824-A1 | Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems | UMPS, NUDT14, NUDT5 | RBP4 3773/4885TTR 4357/4885KDM4E 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.